Zacks Investment Research·3d ago
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedAmneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
Amneal's revenue has grown modestly, reaching $862.7M in 2026Q3 with year-over-year growth of 10.0%, yet gross margin swung from 44.3% in 2026Q1 to 38.7% in 2026Q3 and the company posted a $7.5M net loss in the latest quarter, suggesting earnings quality remains uneven.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue reached $862.7M in 2026Q3 with 10.0% year-over-year growth, but operating margin compressed from 19.8% in 2026Q1 to 11.1% in 2026Q3 and gross margin fell to 38.7%, suggesting operating leverage is fading.
AMRX stock shows strong performance with a notable 52-week high and significant trading volume, indicating investor confidence and market interest.
Comprehensive stock analysis, price targets, and earnings estimates are available for AMRX, providing investors with valuable insights for decision-making.
Amneal Pharmaceuticals is a key player in the pharmaceutical sector, with detailed stock quotes and historical data highlighting its market presence.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.26+9.5% vs $0.24 | $863M+5.5% vs $818M |
Q3 2026 Jul 30, 2026 | $0.30+34.8% vs $0.22 | $796M+3.6% vs $768M |
Q2 2026 May 7, 2026 | $0.27+58.8% vs $0.17 | $723M+0.4% vs $720M |
Q1 2026 Feb 27, 2026 | $0.21+16.7% vs $0.18 | $814M+0.9% vs $807M |
Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Benchmark AMRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amneal Pharmaceuticals, Inc. (AMRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.14 | $6.43B | 45.82 | 8.05% | 4.62% | 82.23% | — | |
| $42.61 | $50.41B | 99.63 | 4.31% | 2.94% | 6.35% | — | |
| $19.91 | $23.19B | -37.62 | -2.98% | -4.13% | -4.24% | 2.41% | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $32.96 | $1.34B | 13.14 | 17.12% | 6.67% | 27.44% | 1.44% | |
| $6.59 | $648.78M | -4.62 | — | — | -67.78% | — |
Amneal Pharmaceuticals, Inc. (AMRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amneal Pharmaceuticals, Inc. (AMRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 10, 2026·SEC
Aug 3, 2026·SEC
Get notified when AMRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amneal Pharmaceuticals, Inc. (AMRX) stock FAQ — growth, dividends, profitability & financials explained
Amneal Pharmaceuticals, Inc. (AMRX) reported $3.20B in revenue over the trailing twelve months. Revenue was $3.02B in fiscal year 2025. That is 248% more than the $866.3M of fiscal year 2015.
Amneal Pharmaceuticals, Inc. (AMRX) grew revenue by 8.9% over the trailing twelve months, compared with the twelve months before.
Yes. Amneal Pharmaceuticals, Inc. (AMRX) earned $147.5M in net income over the trailing twelve months (a 4.6% net margin).
Amneal Pharmaceuticals, Inc. (AMRX) had a return on equity (ROE) of 82.2% over the trailing twelve months. That is well above the market's typical 10-15%.
Amneal Pharmaceuticals, Inc. (AMRX) generated $40.4M in free cash flow over the trailing twelve months.
